The PANVAC vaccine utilizes a modified poxvirus vector to deliver the genetic instructions for these antigens to the immune system, with the aim of provoking an immune response that targets and eliminates cancer cells expressing CEA and MUC1. This evidence concerns the gene MUC1 and cancer.